Javed A, Ajmal M, Wolfson A. Dabigatran in cardiovascular disease management: A comprehensive review. World J Cardiol 2021; 13(12): 710-719 [PMID: 35070113 DOI: 10.4330/wjc.v13.i12.710]
Corresponding Author of This Article
Muhammad Ajmal, MD, Academic Fellow, Department of Cardiology, University of Arizona, 1625 N Campbell Ave, Tucson, AZ 85704, United States. drajmal207@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Dec 26, 2021; 13(12): 710-719 Published online Dec 26, 2021. doi: 10.4330/wjc.v13.i12.710
Dabigatran in cardiovascular disease management: A comprehensive review
Ayesha Javed, Muhammad Ajmal, Aaron Wolfson
Ayesha Javed, Department of Internal Medicine, University of Arizona, Tucson, AZ 85719, United States
Muhammad Ajmal, Department of Cardiology, University of Arizona, Tucson, AZ 85719, United States
Aaron Wolfson, Department of Cardiology, University of Southern California, Los Angeles, CA 90007, United States
Author contributions: Ajmal M came up with the idea; Javed A and Ajmal M drafted the manuscript; Wolfson A reviewed and finalized it; Javed A, Ajmal M and Wolfson A revised the manuscript.
Conflict-of-interest statement: All authors have no any conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Muhammad Ajmal, MD, Academic Fellow, Department of Cardiology, University of Arizona, 1625 N Campbell Ave, Tucson, AZ 85704, United States. drajmal207@gmail.com
Received: April 6, 2021 Peer-review started: April 6, 2021 First decision: September 2, 2021 Revised: September 27, 2021 Accepted: November 25, 2021 Article in press: November 25, 2021 Published online: December 26, 2021 Processing time: 261 Days and 2.5 Hours
Abstract
Dabigatran, a direct thrombin inhibitor, has robust data for the treatment of deep venous thrombosis and pulmonary embolism, stroke prevention in non-valvular atrial fibrillation, and the prophylaxis of venous thromboembolism (VTE) after knee and hip replacement. Recent studies have evaluated dabigatran to determine its safety and efficacy in such conditions as VTE in malignancy, coronary artery disease, mechanical and bioprosthetic valves, and antiphospholipid syndrome. This article provides a comprehensive review on the role of dabigatran in various cardiovascular diseases.
Core Tip: Direct oral anticoagulants (DOACs) have plethora of data for the use in medical field and particulalry in cardiovascular medicine. This review is focused on the dabigatran which is one of the DOAC and it is prudent for all the physicians to be familiar with this drug.
